Portfolio News SIRPant

SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

By WebmasterMarch 12, 2024December 12th, 2024No Comments

SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

See more here

Previous PostMelior Is Recognized as CRO of the Year by Life Sciences Review
Next PostVenatorx Pharmaceuticals Expands Senior Leadership Team

SIRPant Immunotherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating SIRPant-M in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostMelior Is Recognized as CRO of the Year by Life Sciences Review

Next PostVenatorx Pharmaceuticals Expands Senior Leadership Team